| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA860 Maribavir for treating refractory or resistant cytomegalovirus infection after transplant |
|
Medicine details |
|
| Medicine name | maribavir (Livtencity®) |
| Formulation | oral |
| Reference number | 195 |
| Indication | Treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). |
| Company | Takeda UK Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/10/2022 |
| NICE guidance | TA860 Maribavir for treating refractory or resistant cytomegalovirus infection after transplant |
| Commercial arrangement | PAS |